Differential Diagnosis of Lung Cancer, Its Metastasis and Chronic Obstructive Pulmonary Disease Based on Serum Vegf, Il-8 and MMP-9

Overview

Journal Sci Rep

Specialty Science

Date 2016 Nov 5

PMID 27811960

Citations 14

Authors

Murali M S Balla

Sejal Desai

Pallavi Purwar

Amit Kumar

Prashant Bhandarkar

Yogesh K Shejul

C S Pramesh

S Laskar

Badri N Pandey

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) patients are at higher risk of developing lung cancer and its metastasis, but no suitable biomarker has been reported for differential diagnosis of these patients. Levels of serum biomarkers (VEGF, IL-8, MMP-9 and MMP-2) were analyzed in these patients, which were compared with healthy donors (HD). Levels of VEGF (P < 0.005) and MMP-9 (P < 0.05) were significantly higher in COPD patients than HD. Compared to HD, a decrease in IL-8 (~8.1 folds; P < 0.0001) but an increase in MMP-9 (~1.6 folds; P < 0.05) levels were observed in the lung cancer patients. Cancer patients showed significantly (P < 0.005) lower levels of serum VEGF (1.9 folds) and IL-8 (~9 folds) than the COPD patients. VEGF level was significantly higher (2.6 folds; P < 0.0005) in metastatic than non-metastatic cancer patients. However, MMP-2 didn't show significant variation in these patients. The Youden's index (YI) values for lung cancer diagnosis in HD using IL-8 was 0.55 with 83.3% overall accuracy. VEGF was able to diagnose COPD in HD with better YI (0.38) and overall accuracy (70.6%). IL-8 was able to diagnose cancer in COPD patients and HD with YI values of 0.35, 0.55 with 71% and 83.3% overall accuracy, respectively.

Citing Articles

The multifaceted roles of matrix metalloproteinases in lung cancer.

Wei C Front Oncol. 2023; 13:1195426.

PMID: 37766868 PMC: 10520958. DOI: 10.3389/fonc.2023.1195426.

A Potential Serum Biomarker for Screening Lung Cancer Risk in High Level Environmental Radon Areas: A Pilot Study.

Autsavapromporn N, Klunklin P, Chitapanarux I, Jaikang C, Chewaskulyong B, Sripan P Life (Basel). 2021; 11(11).

PMID: 34833148 PMC: 8625497. DOI: 10.3390/life11111273.

Cytokine expression in patients with interstitial lung disease in primary Sjogren's syndrome and its clinical significance.

Yang H Am J Transl Res. 2021; 13(7):8391-8396.

PMID: 34377333 PMC: 8340227.

Alkylating and oxidative stresses in smoking and non-smoking patients with COPD: Implications for lung carcinogenesis.

Shih Y, Chang Y, Cooke M, Pan C, Hu C, Chao M Free Radic Biol Med. 2021; 164:99-106.

PMID: 33418114 PMC: 7897309. DOI: 10.1016/j.freeradbiomed.2020.12.442.

Prognosis of metastasis based on age and serum analytes after follow-up of non-metastatic lung cancer patients.

Balla M, Patwardhan S, Melwani P, Purwar P, Kumar A, Pramesh C Transl Oncol. 2020; 14(1):100933.

PMID: 33188981 PMC: 7670208. DOI: 10.1016/j.tranon.2020.100933.

References

Kanoh Y, Abe T, Masuda N, Akahoshi T . Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A. Oncol Rep. 2012; 29(2):469-73. DOI: 10.3892/or.2012.2123. View

Desai S, Laskar S, Pandey B . Autocrine IL-8 and VEGF mediate epithelial-mesenchymal transition and invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer cells. Cell Signal. 2013; 25(9):1780-91. DOI: 10.1016/j.cellsig.2013.05.025. View

Kurishima K, Satoh H, Ishikawa H, Yamashita Y, Homma T, Ohtsuka M . Lung cancer patients with chronic obstructive pulmonary disease. Oncol Rep. 2000; 8(1):63-5. View

Millar H, Nemeth J, McCabe F, Pikounis B, Wickstrom E . Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2180-7. DOI: 10.1158/1055-9965.EPI-07-2915. View

Harkness L, Kanabar V, Sharma H, Westergren-Thorsson G, Larsson-Callerfelt A . Pulmonary vascular changes in asthma and COPD. Pulm Pharmacol Ther. 2014; 29(2):144-55. DOI: 10.1016/j.pupt.2014.09.003. View

Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T . Early detection of COPD is important for lung cancer surveillance. Eur Respir J. 2011; 39(5):1230-40. DOI: 10.1183/09031936.00126011. View

Gong L, Wu D, Zou J, Chen J, Chen L, Chen Y . Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016; 7(14):18458-68. PMC: 4951301. DOI: 10.18632/oncotarget.7607. View

Infante M, Cavuto S, Lutman F, Brambilla G, Chiesa G, Ceresoli G . A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009; 180(5):445-53. DOI: 10.1164/rccm.200901-0076OC. View

Cao C, Chen Z, Sun S, Yu Y, Ding Q, Deng Z . Evaluation of VEGF-C and tumor markers in bronchoalveolar lavage fluid for lung cancer diagnosis. Sci Rep. 2013; 3:3473. PMC: 3858788. DOI: 10.1038/srep03473. View

10.

King P . Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015; 4(1):68. PMC: 4518022. DOI: 10.1186/s40169-015-0068-z. View

11.

Huang R, Wei Y, Hung R, Liu G, Su L, Zhang R . Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. EBioMedicine. 2016; 2(11):1677-85. PMC: 4740296. DOI: 10.1016/j.ebiom.2015.09.031. View

12.

Sohal S . Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer: Epithelial Mesenchymal Transition (EMT), the Missing Link?. EBioMedicine. 2016; 2(11):1578-9. PMC: 4740323. DOI: 10.1016/j.ebiom.2015.10.016. View

13.

Guo C, Wang S, Deng C, Zhang D, Wang F, Jin X . Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther. 2007; 11(3):183-92. DOI: 10.1007/BF03256240. View

14.

Santos S, Peinado V, Ramirez J, Morales-Blanhir J, Bastos R, Roca J . Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 167(9):1250-6. DOI: 10.1164/rccm.200210-1233OC. View

15.

Hernandez-Montoya J, Perez-Ramos J, Montano M, Ramirez-Venegas A, Sansores R, Perez-Rubio G . Genetic polymorphisms of matrix metalloproteinases and protein levels in chronic obstructive pulmonary disease in a Mexican population. Biomark Med. 2015; 9(10):979-88. DOI: 10.2217/bmm.15.75. View

16.

Zhang Y, Wu J, Zhang J, Xue J, Ma R, Cao H . Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology. Oncol Lett. 2014; 7(2):499-506. PMC: 3881935. DOI: 10.3892/ol.2013.1718. View

17.

Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T . Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res. 2000; 20(2B):1311-6. View

18.

FONTANA R, SANDERSON D, Taylor W, WOOLNER L, Miller W, Muhm J . Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 1984; 130(4):561-5. DOI: 10.1164/arrd.1984.130.4.561. View

19.

Durham A, Adcock I . The relationship between COPD and lung cancer. Lung Cancer. 2015; 90(2):121-7. PMC: 4718929. DOI: 10.1016/j.lungcan.2015.08.017. View

20.

Vant Westeinde S, van Klaveren R . Screening and early detection of lung cancer. Cancer J. 2011; 17(1):3-10. DOI: 10.1097/PPO.0b013e3182099319. View